Table 6.
Transmigration assay.
| Group | MDA-MB-231 | MDA-MB-468 | MCF-7 | BT-474 | SKBR-3 | MCF-10A |
|---|---|---|---|---|---|---|
| LPA 0.1 μM | + | + | + | – | Ø | Ø |
| LPA 1.0 μM | + | + | + | – | Ø | Ø |
|
LPA 0.1 μM + Ki16425 2 μM |
– | – | – | Ø | Ø | Ø |
|
LPA 1.0 μM + Ki16425 2 μM |
Ø | – | – | Ø | Ø | Ø |
|
LPA 0.1 μM + Ki16425 20 μM |
– | – | – | Ø | Ø | Ø |
|
LPA 1.0 μM + Ki16425 20 μM |
– | – | – | Ø | Ø | Ø |
Effect of lysophosphatidic acid (LPA) 18:1 and the LPA receptor 1, 3 (and 2) inhibitor Ki16425 on transmigration of different human breast (cancer) cell lines. n = 2 replicate experiments.
Ø: no effect; +: stimulatory trend; –: inhibitory trend. For LPA 0.1 μM and LPA 1.0 μM stimulation was compared to the control group; for LPA 0.1 μM/LPA 1.0 μM + Ki16425 2/20 μM inhibition was compared to the respective LPA group without Ki16425.